Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 13/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22624596 | 1.00 | PTGES (0.39) | PTGESSLC7A5FFAR1GRM5ABCB1 | |
| SCHEMBL22607824 | 0.86 | FFAR1 (0.40) | PTGESFFAR1GRM5 | |
| SCHEMBL22607823 | 0.86 | FFAR1 (0.40) | PTGESFFAR1GRM5 | |
| SCHEMBL22626719 | 0.80 | FFAR1 (0.44) | PTGESFFAR1 | |
| SCHEMBL29943701 | 0.80 | ACACB (0.34) | PTGESSLC7A5FFAR1GRM5ACACB | |
| SCHEMBL22624582 | 0.80 | ACACB (0.34) | PTGESSLC7A5FFAR1GRM5ACACB | |
| SCHEMBL22607864 | 0.72 | FFAR1 (0.38) | PTGESFFAR1ACACB | |
| SCHEMBL22607867 | 0.72 | FFAR1 (0.38) | PTGESFFAR1ACACB | |
| SCHEMBL22624583 | 0.72 | SLC7A5 (0.45) | PTGESSLC7A5ABCB1 | |
| SCHEMBL22607859 | 0.72 | FFAR1 (0.38) | PTGESFFAR1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667630-B2 | Nitrogen-containing 6-membered cyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-06-06 | — | — | US | disclosed |
| EP-3733665-B1 | 2-OXO-1,3,4-THIADIAZINAN-3-YL MOIETY CONTAINING COMPOUNDS WITH EP4 RECEPTOR AGONIST ACTIVITY | ASAHI KASEI PHARMA CORP (JP) | 2022-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667630-B2 | Nitrogen-containing 6-membered cyclic compound | PTGER4, EPB41, BMP4 | PTGES 70/4885SLC7A5 1621/4885FFAR1 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.